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Abstract 
This study assesses the market structure and competitiveness of Malaysian pharmaceutical 
industry. A panel analysis of 41 pharmaceutical manufacturing firms over 2004-2012 is 
conducted founded on the modified Structure-Conduct-Performance (SCP) framework. Our 
study reveals that the Malaysian pharmaceutical industry is highly concentrated (oligopoly) 
and the major findings are threefold. First, anti-competitive practices subsist among the 
pharmaceutical firms. Major players may have greater control over the markets and 
potentially colluded to gain better profits. Second, selling intensity is evident to raise the 
firms’ business performance, suggesting that advertisement, marketing campaigns, product 
differentiations and distribution efforts could be effective in building competencies over the 
rivals. Third, the study has tackled the endogeneity problem of traditional SCP with dual 
causal effects found between business conduct and business performance. Firms and 
authorities should consider the interactive mutual influences of structure-conduct-
performance when formulating their respective management decisions and regulatory rules. 
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Introduction 
 
Pharmaceutical industry is of strategic importance for the development of health care sector 
with high potential growth in both global and local platforms due to its relation with the 
public welfare and wellbeing. In Malaysia, the production, imports and sales of 
pharmaceuticals including traditional medicines are regulated by Ministry of Health. There 
are currently 251 manufacturers licensed by the Drug Control Authority (NPCB, 2013). Of 
these, only 74 are licensed to produces pharmaceuticals including for veterinary and OTC 
external while the remaining of 177 manufacturers licensed to produce traditional medicines.  
 
At present stage, there are no policies to regulate medicines pricing as Malaysia 
practices ‘free-market economics’ where manufacturers, distributors and retailers are free to 
set their own prices without government control (Babar et.al, 2007). Nevertheless, complaints 
arise from industry players as there are anti-competitive practices along the pharmaceutical 
supply chain. Some of the big buyers get their products at an extremely low price and sell to 
the public with only small markup in the short run, causing the small pharmacies with sole 
ownership losing competency. Further, dominant multinational pharmaceutical manufacturers 
solely sell the higher dose of certain medicines to clinics, although it is an over-the-counter 
product and that is anti-competitive practices (NST, 2011). Manipulations in prices are also 
found among different sectors and geographical areas. For instance, the high price variations 
are observed for some identical products in private pharmacies and dispensing doctors’ 
clinics (Babar et.al, 2007). 
 
Persisting of anti-competiveness issues in the pharmaceutical market may form unfair 
competition for the existing small and medium size manufacturers when competing with the 
big players. This scenario may demotivate them from investing and expanding their business 
and creates barriers for new entrants. This unhealthy condition can retard economic 
development and growth in the pharmaceutical industry.  
 
In addition, without proper regulation it is foreseen once the small players lost their 
battles, big players will look for instant elevated profits with high mark-ups. Such move will 
drive up the medicines price by sellers and make medicines less affordable to people in need 
especially those at the bottom millions. The implication on both economic development and 
public welfare should alert the regulatory authority to impose laws that promote vigorous and 
3 
 
healthy competition within the pharmaceutical industry. But in order for the law enforcement 
to be effective, a thorough and in depth study is required to examine the pharmaceutical 
market structure and the firms’ business behavior in achieving their profitability.  
 
The most commonly used model to tackle such issue is the Structure-Conduct-
Performance (SCP) paradigm. SCP is one of the structural approaches which was derived 
from neoclassical analysis of market competition and originally used by the US government 
in crafting antitrust regulations (Shaik, et. al, 2009). There is a strand of literature devoted to 
the discussion and application of the modified SCP on various industry structures. 
Nevertheless, the growing literature mostly focuses on the developed countries and banking 
sector such as Athanasoglou et.al (2006), Maniatis (2006), Mensi & Zouari (2011), Park 
(2012), Behname, (2012) and Ferreira (2014). Lesser attention has been paid to the 
developing nations. Among them, Tung et. al (2010) studied the hotel industry in Taiwan, 
Ding, et. al (2011) employed modified SCP on the China automobile industry, Lee (2012) 
explored the causal relationship of SCP on the Taiwanese CPA industry, whereas Sarita et al 
(2012) and Sahoo & Mishra (2012) examined the Indonesian and Indian banking sector 
respectively. Their findings have generally supported the modern SCP but the causal effects 
across elements of structure-conduct-performance are rather indecisive and vary by industries. 
 
Thus far, there are limited studies on pharmaceutical industry in developing nations. 
Among the cited studies are Zhang, et al. (2009), Mishra & Chandra (2010), Mishra & Vikas 
(2010) and Vyas et al. (2012) but only works by Mishra & Chandra (2010) and Mishra & 
Vikas (2010) are related to the SCP paradigm. Zhang, et al. (2009), for instance, surveyed the 
human resource perception on work practices and firm performance of pharmaceutical 
industry in China while Vyas, et al. (2012) scrutinized the determinants of merger and 
acquisition (M&A) in Indian pharmaceutical industry over 2001-2010 using logit analysis. A 
more relevant study by Mishra & Chandra (2010) on 52 Indian pharmaceutical companies 
revealed that firms with greater selling efforts were found to have significant and positive 
influences on firms’ profitability. Higher expenses spent in the selling strategies such as 
advertising to disseminate the information and better reach to consumers will result in higher 
profit margin. Based on modified SCP, Mishra & Vikas (2010) assessed 176 pharmaceutical 
companies and, agreed that selling intensity is positively related with the firm profitability but 
firms’ profitability also shows negative effect to the selling intensity. The finding implies 
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two-way correlation between conduct and performance variables which in turns support the 
modified SCP paradigm. 
 
To our best knowledge so far, there is no SCP related study being conducted for the 
Malaysian pharmaceutical industry. Babar et. al (2007) did a comprehensive study on 
medicine prices and drug costs and their availability and affordability in Malaysia but did not 
assess the market structure and organization behavior of the pharmaceutical industry. This 
paper therefore contributes as pioneer study that fills an important gap in existing literature 
that allows a better and updated analysis of the pharmaceutical industry dynamics, which 
demonstrates how exogenous structural changes feed into the competition process in 
Malaysia. This will help the Malaysian regulatory authorities to formulate policies that would 
improve and sustain healthy competition among the pharmaceutical players, and hence 
enhance the public welfare. 
 
This paper is structured into four sections follows: Section 2 presents the modified 
SCP theoretical framework and methodology applied, which include the three functional 
models, measurements of the variables and data used; Section 3 then discusses the empirical 
results; Section 4 concludes the paper. 
 
Theoretical Framework and Methodology 
 
The SCP framework is widely adopted to evaluate the competitive industries by investigating 
the structure of industry relates to the firm behaviours (conduct) and performance (Umar 
Mu’azu, 2013). But the unidirectional relationship of structure-conduct-performance in the 
traditional SCP entailed with endogeneity problem has raised many criticisms by economic 
theorists. With successive development in the industrial organization literature, the modified 
or modern SCP paradigm suggests dual or multi causalities exist between variables of market 
structure, business conduct and business performance. The interdependencies amongst these 
variables make them endogenous in nature (Sahoo & Mishra, 2012; Umar Mu’zu, 2013). 
Inclusion of public policies with relates to taxes, subsidies, international trade, investment 
and other terms is another important development in the modern SCP paradigm. The 
modified SCP which addresses the shortcomings of traditional SCP is adopted as the key 
theory of the present research. However, assessment of public policies is not included in our 
analysis because the industry is far from being regulated and the 2010 Competition Act was 
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only implemented since January 2012 that the impact is still unforeseen. Figure 1 depicts the 
modified SCP paradigm that shows multidirectional relationship among the variables.  
[Figure 1] 
 
Data 
In this study, the three functional models specified in the next section are estimated with 
panel dataset of 41 pharmaceutical firms operating in Malaysia for the period of 2004-2012. 
These data are sourced from the firms’ annual reports submitted to Company Commission of 
Malaysia (CCM). The data availability for the years of 2004, 2005, 2006 and 2012 are 
inconsistent, therefore, this study has to work with an unbalanced panel data set for the period 
of 2004-2012. The data are reviewed and crosschecked before relevant values are extracted 
and used for empirical analysis. 
 
Measurement of Variables 
Various measurements are being used in numerous SCP studies. This study adopts the 
measurements that are relevant and fit most to the research. Details of the variables are 
presented in Table 1. 
[Table 1] 
 
Establishment of Functional Models 
Modified SCP deals with multidirectional effects, thus all three elements of market structure, 
business conduct and business performance can act as dependent variables as well as 
independent variables respectively. The three equations and related variables that applied in 
the functional models can be rewritten as follows: 
 
i) Market structure:𝑆𝑖 =  𝑎0 + 𝑎1𝐶𝐴𝑃𝑖𝑡 + 𝑎2𝑆𝐸𝐿𝐿𝑖𝑡 + 𝑎3 𝑅𝑂𝑆𝑖𝑡 + 𝑎4𝑅𝑂𝐴𝑖𝑡 + 𝑒1 
where market structure (HHI, SHARE) is dependent variables and there are four 
independent variables in this model; i = 1,2 ;  𝑆1 =  𝐻𝐻𝐼  , 𝑆2 = 𝑆𝐻𝐴𝑅𝐸𝑖𝑡  ; a0 is the 
intercept; a1,....,a4 are the parameters of the regression model; e1 is the error term. 
 
ii) Firms’ conduct: 𝐶𝑖 =  𝑏0 + 𝑏1𝐻𝐻𝐼 + 𝑏2 𝑆𝐻𝐴𝑅𝐸𝑖𝑡 + 𝑏3𝑅𝑂𝑆𝑖𝑡 + 𝑏4𝑅𝑂𝐴𝑖𝑡 + 𝑒2 
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where business conduct (CAP, SELL) is dependent variable and there are four 
independent variables in this model; i = 1, 2;𝐶1 = 𝐶𝐴𝑃𝑖𝑡, 𝐶2 = 𝑆𝐸𝐿𝐿𝑖𝑡 ; b0 is the intercept; 
b1,....,b4 are the parameters of the regression model; e2 is the error term. 
 
iii) Firms’ performance:𝑃𝑖 =  𝑐0 + 𝑐1𝐻𝐻𝐼 + 𝑐2𝑆𝐻𝐴𝑅𝐸𝑖𝑡 + 𝑐3𝐶𝐴𝑃𝑖𝑡 + 𝑐4𝑆𝐸𝐿𝐿𝑖𝑡 + 𝑒3  
where business performance (ROS, ROA) is the dependent variable and there are four 
independent variables in this model; i = 1,2 ; 𝑃1 = 𝑅𝑂𝑆𝑖𝑡  , 𝑃2 = 𝑅𝑂𝐴𝑖𝑡  ;  c0 is the 
intercept; c1,....,c4 are the parameters of the regression model; e2 is the error term. 
 
Empirical Results and Discussion 
 
Classification of Market Structure 
Following established literature, Herfindahl-Hirschman Index (HHI) is employed to measure 
the degree of market concentration in Malaysian pharmaceutical industry. Figure 1 depicts 
the HHI trend of 41 pharmaceutical firms over 2004-2012. Meanwhile, Table 2 classifies the 
market structure by HHI in accordance to the US Merger Guidelines. Apparently, the 
pharmaceutical manufacturing firms fall in the HHI range of 2240-2616 with an upward trend. 
This postulates a highly concentrated market (oligopoly) that may encourage dominant firms 
to collude through unofficial collaboration and thus weaken the market competition. A 
warning sign arises that the 2010 competition act failed to avert the HHI from growing. Such 
finding implies a low consumer bargaining power that allows major firms to gain greater 
profits by charging higher prices of medical drugs and pharmaceutical products. The fact is 
also supported by Babar et.al (2007)’s earlier arguement that anti-competitive practices 
presence along the pharmaceutical supply chain, creating barriers for the small and medium 
size manufacturers to compete with the big players.  
[Figure 2] 
[Table 2] 
 
The following Table 3, 4, and 5 demonstrate the panel regression of three SCP 
functional models. Each of these models employs two dependent variables to represent the 
SCP elements of market structure, business conduct and business performance. HHI and 
market share (SHARE) embody the market structure, capital intensity (CAP) and selling 
intensity (SELL) exemplify the business conduct, whereas return on sales (ROS) and return 
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on assets (ROA) correspond to the business performance. Together, there will be six 
equations to be estimated. 
 
Before we proceed, a few scientific points are worth notified. First, R2 has a very 
modest role in the panel regression. Neither is a high value of R2 evidence in favour of a 
model nor is a low value of the R2 evidence against it (Gujarati & Sangeetha, 2007; Sahoo & 
Mishra, 2012). Second, since our panel dataset has greater N than T (cross sectional units > 
time series units), we select our panel regression from two alternative models namely the 
Fixed Effect (FE) model and Random Effect (RE) model is highly suggested in the literature. 
Hausman test is therefore conducted as diagnostic test and depicted in Table 3, 4, and 5. It is 
observed that the RE estimate of the cross section variance term is zero, so that there do not 
appear to be RE in all three functional models. Thus, null hypothesis is rejected and FE panel 
regression is more appropriate to be employed in this study.  
[Table 3] 
 
Market structure equations report interesting results via Table 3. When HHI is treated 
as dependent variable, it is significantly affected by the lagged return on sales (ROS) but 
none of the business conduct variables (CAP, SELL) shows significant influence. Still, no 
direct or clear conclusion can be drawn due to the miniature and indecisive coefficients of 
negative ROS (-1) and positive ROS (-2).  
 
When market share (SHARE) is taken as dependent variable, ROA coefficient is 
positive and significant but small in value (0.01), suggesting that pharmaceutical firms with 
better financial performance specifically higher return on assets tend to raise their market 
share in the industry at small proportional rate. Other firms with lower financial performance 
may find it difficult to grow and the growth of market share creates some barriers for new 
entrants. Though the impact is small, the positive relationship is in line with the view of SCP 
literature (Mishra & Chandra, 2010; Lee, 2012). But again, the business conduct variables are 
absent from the direct effects on market share. In brief, the firms’ business performance has 
some but minor impacts on the market structure of pharmaceutical industry. 
[Table 4] 
 
The results of the business conduct equations are presented in Table 4. We observe 
that out of the two market structure variables (HHI, SHARE), only HHI shows negative and 
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significant impact on SELL but not on CAP. This postulates that pharmaceutical firms in 
highly concentrated market tend to reduce the expenses on selling strategies. It is possible as 
higher concentration leads to less competition, causing complacent among the major firms 
and they feel unnecessary to invest or put in more efforts on selling strategies. On the other 
hand, ROS shows negative and significant impact on CAP but not on SELL, implying higher 
return on sales leads to lower capital investment. However, ROA has no significant effect on 
either CAP or SELL. Overall, the results of business conduct in Table 4 suggest that a highly 
concentrated pharmaceutical market with less competition but with better return on sales 
would have less motivation to inject more capital investment and selling expenses. 
 
The finding of business performance is depicted in Table 5. HHI and SHARE show 
significant and positive effect on ROS and ROA respectively. This may suggests that firms in 
more concentrated market gain better return on sales, whereas firms with larger market share 
create better financial performance in term of return on assets and it is in line with the general 
perception of SCP. In addition, the panel regression reveals that SELL has significant 
positive influence on both ROS and ROA. The higher the expenses spend on the selling 
strategies such as advertisement, marketing promotion, product differentiations and 
distribution related efforts help to raise the financial performance of pharmaceutical firms as 
selling strategies is one of strategic behaviour in creating competitive edges over the rivals. 
For instances, advertisement and marketing promotion assist in building brand image 
advantages and product differentiations, which in turn generate greater businesses and profits 
to the firms. In contrast, CAP – the business conduct variable, shows significant but negative 
effects of on both ROS and ROA. This postulates that the more intense the capital invested 
by pharmaceutical firms, the lower returns on sales and assets. This may be possible due to 
the under-utilization of capital investment to generate higher productivity or to create better 
profits. In a nutshell, the structure of pharmaceutical industry and the firms’ operations do 
shed some impacts on their business performance, but at different manner. 
[Table 5] 
 
So far, our panel regression has analyzed and contextualized the competitive 
conditions of the Malaysian pharmaceutical industry by examining how the underlying 
market structure was related to, and affected the conduct and performance of pharmaceutical 
firms. Nonetheless, regression does not tell about the causal effects among the variables. Yet, 
the modified SCP paradigm proposes dual or multidirectional causalities among the structure-
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conduct-performance relationship. In other words, the three elements of SCP are no longer 
exogenous. Instead, the whole SCP is influenced by the demand and supply related 
conditions that in turn depend on the market structure and firms’ conduct, as well as the firms’ 
performance. Besides, the modern SCP relationship may not necessarily be instantaneous in 
nature as there may be existed of lagged relationship among the variables. For instance, the 
market structure may be influenced by the lagged conduct or performance over a period of 
time making the relationship dynamic in the nature (Mishara & Behera, 2007).  
 
Our study stands out differently from the previous studies that applied simultaneous 
equations for modified SCP (see Mishra, P. & Vikas, 2010; Tung et. al, 2010; among others). 
Instead, Panel Granger Causality test (with lagged effect) is employed in this study to 
examine the causality relationship, following the recent study by Ferreira (2014) who 
explores bank efficiency and market concentration in the European Union. Panel Granger 
Causality tests the causality running within and between the six variables in the three SCP 
functional models. Together, there will be 15 combinations of Granger-typed null hypotheses 
to be estimated. 
 
The panel causality results are summarized and graphically represented by Figure 3. 
While causal effects are more evident among variables of business conduct and business 
performance, the market structure variables are rather weak and exogenous in causalities. For 
instance, there is only one-way causality running from market share to capital intensity 
whereas the HHI is totally absent from the causal effect. Such result is somewhat consistent 
with the earlier panel regression reported. On the other hand, business conduct appears to be 
Granger-caused by business performance and vise versa. Both capital intensity (CAP) and 
selling intensity (SELL) are Granger-caused by return on assets (ROA) by lagged one-period 
effect. At the same time, there is one-way causality running from return on sales (ROS) to 
SELL while two-way causal effect is confirmed between CAP-ROA at 1% significant level. 
In addition, we also observe causality effects present within the business variables and 
business performance, e.g. one-way causality from CAP to SELL and two-way causality 
between ROS-ROA. In brief, the findings imply at least dual causal effects appear among the 
business conduct and business performance in the pharmaceutical industry. This in fact 
verifies the modified SCP paradigm and tackles the endogeneity problem of the conventional 
SCP approach. 
[Figure 3] 
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Conclusions and Implications 
 
In the backdrop of free economic practices but unfair competition in the pharmaceutical 
industry, this study makes a pioneer attempt to assess its market structure and 
competitiveness using the modified SCP model. A panel analysis of 41 pharmaceutical firms 
over 2004-2012 was conducted. The major findings are threefold. 
 
First, it is observed that the Malaysian pharmaceutical market is classified as highly 
concentrated (oligopoly) and the market concentration is significantly affected by the lagged 
return on sales while the firms’ market share is driven by the return on assets. Somehow, the 
market structure is not influenced by the firms’ business conduct but determined by their 
business performance. Major players in the pharmaceutical industry may have greater control 
over the markets and potentially colluded to manipulate medicine prices. Unfair competition 
for medium and small players in the industry may arise if the scenario persists. Furthermore, 
the high priced medicines and drugs may lead to social implication on the consumer welfare 
as they may suffer from buying expensive medicines which in turn increase their living 
expenses. Hence, it is necessary for regulation authority to implement some necessary 
measures to ensure a healthy competition in the pharmaceutical sector.  
 
Second, in term of business conduct, selling intensity is evident to raise the firms’ 
business performance. Thus, the selling strategies such as advertisement, marketing 
campaigns, product differentiations and distribution relation efforts could be effective tool for 
the pharmaceutical firms in creating competitive advantages over their rivals which in turn 
raise their return on sales. Third, active and two-way Granger-typed causal effects are found 
between the business conduct and the business performance of pharmaceutical firms. This 
verifies the modified SCP relationship and tackles the endogeneity problem of the traditional 
SCP approach. Firms and authorities should consider the interactive mutual influences of 
structure-conduct-performance when formulating respective management decisions and 
regulatory rules. The present study provides findings that shed new insights and valuable 
implications. They are useful not only for the policymakers but also for existing players, 
potential entrants and other stakeholders of the pharmaceutical industry. 
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Figure 1:  Modified Structure-Conduct-Performance-Policy Paradigm 
 
Source: Reproduced from Mishra & Vikas (2010) 
 
Table 1: Definition and Measurement of Variables 
SCP Elements Variables Definitions 
Market Structure 
HHI = ∑ 𝑆𝐻𝐴𝑅𝐸𝑖
2  ,
𝑛
𝑖=1
 
where SHAREi is the market share of the ith 
pharmaceutical firm, and n is the total number of 
pharmaceutical firms for every year. 
𝑆𝐻𝐴𝑅𝐸𝑖𝑡 =
𝑅𝐸𝑉𝑖𝑡
∑ 𝑅𝐸𝑉𝑖𝑡
𝑛
𝑖=1
 
where REVit is the total sale revenues of the 
pharmaceutical firm i in year t and n is the total number 
of pharmaceutical firms for every year. 
Business 
Conduct 
𝐶𝐴𝑃𝑖𝑡 =
𝐴𝑆𝑆𝐸𝑇𝑆𝑖𝑡
𝑅𝐸𝑉𝑖𝑡
 
where ASSETSit is the  total assets of the pharmaceutical 
firm i in year t and  REVit is the total sales revenues of 
the pharmaceutical firm i in year t . 
𝑆𝐸𝐿𝐿𝑖𝑡 =  
𝑆𝐸𝑖𝑡
𝑅𝐸𝑉𝑖𝑡
 
where SEit is the total expenses for selling purpose 
(advertisement, marketing and distribution) of the ith 
pharmaceutical firm in year t and REVit is the total 
revenues of the ith pharmaceutical firm in year t. 
Business 
Performance 
𝑅𝑂𝑆𝑖𝑡 =  
𝑃𝐵𝐼𝑇𝑖𝑡
𝑅𝐸𝑉𝑖𝑡
 
where PBITit  is the  profit before interest and tax of the 
pharmaceutical firm i in year t and REVit is the total 
sales revenues of the pharmaceutical firm i in year t . 
𝑅𝑂𝐴𝑖𝑡 =  
𝑃𝐵𝐼𝑇𝑖𝑡
𝐴𝑆𝑆𝐸𝑇𝑆𝑖𝑡
 
where PBITit is the profit before interests and taxes of 
the ith  pharmaceutical firm in year t and ASSETit is the 
total assets of the ith pharmaceutical firm in year t. 
Source: Reproduced and modified from Lee (2012), Sahoo & Mishra (2012) and Mishra & Vikas (2010). 
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Figure 2: Degree of Market Concentration (HHI), 2004-2012 
 
Source: own calculation based on annual reports’ sales figures. 
 
 
Table 2: Classification of Market Structure by HHI 
Type of Market Structure Range of HHI 
Highly Competitive Market HHI < 100 
Low Concentration Market HHI < 1000 
Moderately Concentrated Market 1000 ≤ HHI <1800 
Highly Concentrated market HHI ≥ 1800 
Source: Adopted from Lu & Liu (2012), Ferreira (2014) and Tililayo and Victor (2014) 
 
 
Table 3: Functional Model of Market Structure (HHI and Market Share) 
Independent 
Variables 
Dependent Variable 
HHI SHARE 
     
Intercept -4.16 (-0.67) 0.03 (69.15)*** 
HHI (-1) 1.75 (2.26)**   
HHI (-2) -0.21 (-0.90)   
CAPit-1 (-1) -0.00 (-1.64) -0.00 (-0.07) 
CAPit-2 (-2) 0.00 (1.51)   
SELLit-1 (-1) 0.01 (0.21) 0.00 (0.07) 
SELLit-2 (-2) -0.05 (-1.62)   
ROSit-1 (-1) -0.02 (-1.87)* -0.00 (-1.11) 
ROSit-2 (-2) 0.01 (2.49)**   
ROAit-1  (-1) 0.00 (0.10) 0.01 (2.83)*** 
ROAit-2 (-2) -0.03 (-1.26)   
     
 Diagnostic Tests 
R2 0.60 0.99 
Adjusted R2 0.51 0.99 
F-Statistic 6.12 600.46 
FE Statistic 0.25 650.49 
Hausman 2 0.00 0.00 
N 246 324 
***, **, * Statistically significant at 1 percent, 5 percent, and 10 percent respectively. 
Reported in parentheses (  ) are t-statistics. 
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Table 4: Functional Model of Business Conduct (CAP and SELL) 
Independent 
Variables 
Dependent Variable 
CAP SELL 
     
Intercept 329.05 (1.44) 1.81 (2.19)** 
HHI -41.53 (-1.43) -0.22 (-2.11)** 
SHARE 9.71 (0.67) 0.06 (0.76) 
ROS -2.40 (-2.66)*** -0.00 (-0.79) 
ROA -39.44 (-1.12) -0.12 (-0.79) 
     
 Diagnostic Tests 
R2 0.39 0.37 
Adjusted R2 0.30 0.27 
F-Statistic 4.12 3.75 
FE Statistic 1.09 3.77 
Hausman 2 0.00 0.00 
N 324 324 
***, **, * Statistically significant at 1 percent, 5 percent, and 10 percent respectively. 
Reported in parentheses (  ) are t-statistics. 
 
 
 
Table 5: Functional Model of Business Performance (ROS and ROA) 
Independent 
Variables 
Dependent Variable 
ROS ROA 
     
Intercept -89.25 (-1.75)* -0.72 (-1.28) 
HHI 10.57 (1.66)* 0.10 (1.31) 
SHARE 0.51 (0.12) 0.76 (4.71)*** 
CAP -0.33 (-4.47)*** -0.01 (-3.44)*** 
SELL 90.95 (4.94)*** 0.20 (2.11)** 
     
 Diagnostic Tests 
R2 0.68 0.58 
Adjusted R2 0.63 0.51 
F-Statistic 13.75 8.72 
FE Statistic 5.52 8.28 
Hausman 2 0.00 0.00 
N 324 324 
***, **, * Statistically significant at 1 percent, 5 percent, and 10 percent respectively. 
Reported in parentheses (  ) are t-statistics. 
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Figure 3: Graphical Representation of Panel Granger Causality Effects 
 
 
 
 
